CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Indication||Myelodysplastic Syndromes (MDS)|
|Funding Request||INQOVI (decitabine and cedazuridine) is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups.|
|Clarification||The timeline of the review has been temporarily suspended, pending the receipt of additional information from the sponsor.|
|Pre Noc Submission||No|
|NOC Date||July 7, 2020|
|Manufacturer||Taiho Pharma Canada, Inc.|
|Sponsor||Taiho Pharma Canada, Inc.|
|Submission Date||October 9, 2020|
|Stakeholder Input Deadline ‡||October 26, 2020|
|Check-point meeting||January 14, 2021|
|pERC Meeting (target date)|
|Initial Recommendation Issued (target date)|
|Feedback Deadline (target date) ‡|
|pERC Reconsideration Meeting (target date)|
|Final Recommendation Issued (target date)|
|Notification to Implement Issued|
|Therapeutic Area||Myelodysplastic Syndromes (MDS)|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.